Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement




May
06
Today In Oncology
Advanced CKM Syndrome Associated With Greater Cancer Risk
Integrated Molecular Analysis Identifies Determinants of Outcomes in TP53-Mutated DLBCL
Adjuvant Hepatic Arterial Infusion After Surgery for Four or More Colorectal Liver Metastases
Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States
AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo